Advances in antibody-mediated rejection of renal allografts
Antibody-mediated rejection (AMR) remains a major obstacle to long-term kidney allograft survival. It does not arise from a single pathway. Preformed or de novo donor-specific antibodies (DSA), endothelial injury, microvascular inflammation, complement…